Business Context and Reporting Period
This Form 8-K is filed by Eyenovia, Inc. (not Hyperion DeFi, Inc.) on September 14, 2021. The report details the entry into material definitive agreements regarding the licensing of the product MydCombi in Greater China and South Korea.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. Specific financial terms disclosed include:
- Upfront Payment: $250,000 to be received from Arctic Vision within three business days.
- Milestone Payments: Up to $2 million in aggregate potential payments from Arctic Vision contingent on development and regulatory milestones.
- Royalties: Future royalty payments on sales from Arctic Vision.
- Outflows: Payments to Senju Pharmaceutical Co., Ltd. based on non-royalty license revenue and sales revenue resulting from the territorial exclusions.
Material Changes
The primary material change is the expansion of the Company's licensing strategy through two amendments executed on September 14, 2021:
- Amendment 1 (Arctic Vision): Granted Arctic Vision exclusive rights to research, develop, manufacture, and commercialize MydCombi in Greater China and South Korea.
- Amendment 2 (Senju Pharmaceutical): Excluded Greater China and South Korea from Senju's existing exclusive territory to accommodate the new agreement with Arctic Vision.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of general risks. The agreements are subject to the satisfaction of certain conditions and the achievement of specific development and regulatory milestones for the milestone payments to be realized.
Investor Verification Checklist
- Verify the receipt of the $250,000 upfront payment from Arctic Vision in the next quarterly report.
- Monitor the specific development and regulatory milestones required to trigger the up to $2 million in milestone payments.
- Review the upcoming Form 10-Q for the period ended September 30, 2021, for the full text of Amendment 1 and Amendment 2.
- Assess the impact of the new royalty-sharing arrangement with Senju Pharmaceutical on future net revenue from the Greater China and South Korea territories.